NDA submitted June 1 for lopinavir/ritonavir protease inhibitor combination for HIV. Abbott is seeking an accelerated approval based on ongoing Phase II and III studies testing the protease inhibitor in combination with other antiretroviral agents for both experienced and naive patients. The company claims that lopinavir boosted by ritonavir produces considerably higher protease inhibitor blood levels than previous agents. Abbott markets ritonavir as Norvir
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth